Your session is about to expire
← Back to Search
Unknown
AND017 for Kidney Anemia
Phase 2
Waitlist Available
Research Sponsored by Kind Pharmaceuticals LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline and at week 2, 4, 6, 8, 10, 12, 14, and 28 days after the last dose
Summary
This trial is testing a new oral medication called AND017 to see if it can safely and effectively treat anemia in patients with chronic kidney disease who are not on dialysis.
Eligible Conditions
- Kidney Anemia
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline and at week 3, 6, 9, 12, 14, and 28 days after the last dose
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline and at week 3, 6, 9, 12, 14, and 28 days after the last dose
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Rate of rise in hemoglobin for each of 3 dose levels as compared with placebo from baseline to 5 weeks after TIW oral dosing
Safety Evaluations
Secondary study objectives
Change from baseline in Hb
Change in hemoglobin levels from baseline to the mean of weeks 10-13
Cumulative incidence of lack of response over the entire treatment period
+12 moreTrial Design
4Treatment groups
Experimental Treatment
Placebo Group
Group I: AND017 Dose CExperimental Treatment1 Intervention
AND017 will be administrated orally at dose C
Group II: AND017 Dose BExperimental Treatment1 Intervention
AND017 will be administrated orally at dose B
Group III: AND017 Dose AExperimental Treatment1 Intervention
AND017 will be administrated orally at dose A
Group IV: PlaceboPlacebo Group1 Intervention
Placebo will be administrated orally
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
AND017
2021
Completed Phase 2
~130
Find a Location
Who is running the clinical trial?
Kind Pharmaceuticals LLCLead Sponsor
8 Previous Clinical Trials
527 Total Patients Enrolled
Yusha Zhu, MD PhDStudy DirectorKind Pharmaceuticals LLC
3 Previous Clinical Trials
153 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger